Literature DB >> 34686918

The influence of antineoplastic agents on the peri-implant bone around osseointegrated titanium implants: an in vivo histomorphometric and immunohistochemical study.

Henrique Rinaldi Matheus1,2, Edilson Ervolino2,3, David Jonathan Rodrigues Gusman1,2, Luiz Guilherme Forin1,2, Bianca Rafaeli Piovezan1,2, Juliano Milanezi de Almeida4,5.   

Abstract

BACKGROUND AND
OBJECTIVE: The interaction between antineoplastic drugs used for treating cancer and non-affected tissues remains poorly assessed and may be critical for maintaining the quality of life for patients during and after treatment. This pre-clinical study evaluated the effects of cisplatin (CIS) and 5-fluorouracil (5-FU) on the peri-implant repair process around osseointegrated titanium implants installed in the tibiae of rats.
MATERIAL AND METHODS: Were used 90 male rats, randomly divided into three groups (n = 30): physiological saline solution (PSS), CIS, and 5-FU. Titanium implants (4.0 × 2.2 mm) were inserted in both tibiae of all animals at day 0. The animals received either PSS, CIS, or 5-FU at 35 and 37 days. Euthanasia was performed at 50, 65, and 95 days after surgery. Histometric (bone/implant contact [BIC]) and bone area fraction occupancy (% BAFO), histological, and immunohistochemical (for bone morphogenetic protein 2/4 [BMP2/4], Runt-related transcription factor 2 [RUNX2], osteocalcin [OCN], and tartrate-resistant acid phosphatase [TRAP]) analyses were performed. Data were statistically analyzed.
RESULTS: Groups CIS and 5-FU presented lower BIC and lower BAFO as compared with PSS in all time points. The imbalance in bone turnover was observed by the lower number of BMP2/4-, RUNX2-, and OCN-positive cells/mm2 and the higher number of TRAP-positive cells/mm in groups CIS and 5-FU as compared with PSS in all time points. Persistent and exacerbated inflammation was observed in groups CIS and 5-FU.
CONCLUSIONS: Both antineoplastic agents interfered negatively in the bone turnover around osseointegrated titanium implants. CLINICAL RELEVANCE: Closer and more careful follow-up of patients with osseointegrated implants that will undergo chemotherapy with either CIS or 5-FU shall be performed.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antineoplastic agents; Bone implant interface; Cisplatin; Fluorouracil; Osseointegration

Mesh:

Substances:

Year:  2021        PMID: 34686918     DOI: 10.1007/s00784-021-04239-2

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.606


  37 in total

Review 1.  Success of dental implants in smokers and non-smokers: a systematic review and meta-analysis.

Authors:  V Moraschini; E dS Porto Barboza
Journal:  Int J Oral Maxillofac Surg       Date:  2015-09-15       Impact factor: 2.789

2.  Investigation of the risk factors associated with the survival rate of dental implants.

Authors:  Sirmahan Cakarer; Firat Selvi; Taylan Can; Irem Kirli; Alen Palancioglu; Basak Keskin; Mehmet Yaltirik; Cengizhan Keskin
Journal:  Implant Dent       Date:  2014-06       Impact factor: 2.454

3.  The Effects of Systemic Diseases and Medications on Implant Osseointegration: A Systematic Review.

Authors:  Tara Aghaloo; Joan Pi-Anfruns; Alireza Moshaverinia; Danielle Sim; Tristan Grogan; Danny Hadaya
Journal:  Int J Oral Maxillofac Implants       Date:  2019 Suppl       Impact factor: 2.804

Review 4.  Association between diabetes mellitus/hyperglycaemia and peri-implant diseases: Systematic review and meta-analysis.

Authors:  Alberto Monje; Andres Catena; Wenche S Borgnakke
Journal:  J Clin Periodontol       Date:  2017-05-05       Impact factor: 8.728

5.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Authors:  Jochen H Lorch; Olga Goloubeva; Robert I Haddad; Kevin Cullen; Nicholas Sarlis; Roy Tishler; Ming Tan; John Fasciano; Daniel E Sammartino; Marshall R Posner
Journal:  Lancet Oncol       Date:  2011-01-11       Impact factor: 41.316

Review 6.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

7.  Implant survival rates for oral and maxillofacial surgery residents: a retrospective clinical review with analysis of resident level of training on implant survival.

Authors:  Maico D Melo; Hamid Shafie; George Obeid
Journal:  J Oral Maxillofac Surg       Date:  2006-08       Impact factor: 1.895

8.  Outcomes of dental implants placed in a surgical training programme.

Authors:  L P Smith; M Ng; D Grubor; A Chandu
Journal:  Aust Dent J       Date:  2009-12       Impact factor: 2.291

9.  Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.

Authors:  André B P van Kuilenburg; Rutger Meinsma; Bernard A Zonnenberg; Lida Zoetekouw; Frank Baas; Koichi Matsuda; Nanaya Tamaki; Albert H van Gennip
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

10.  Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

Authors:  J B Vermorken; F Peyrade; J Krauss; R Mesía; E Remenar; T C Gauler; U Keilholz; J P Delord; P Schafhausen; J Erfán; T H Brümmendorf; L Iglesias; U Bethe; C Hicking; P M Clement
Journal:  Ann Oncol       Date:  2014-03       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.